mp.weixin.qq.com·· 12 hours agoPickScore92
Hengrui HER3-ADC Extends PFS After EGFR-TKI Failure in EGFR-Mutant Advanced NSCLC in HERON-Lung01
In brief
In the interim analysis of the phase 3 HERON-Lung01 trial, Hengrui's HER3-ADC significantly prolonged progression-free survival versus platinum-based chemotherapy in patients with EGFR-mutant advanced NSCLC after progression on EGFR-TKI therapy, meeting the primary endpoint.
Why it matters
Randomized controlled HERON-Lung01 directly compares the HER3-ADC with platinum chemotherapy, with interim PFS, ORR and ILD data informing options after EGFR-TKI progression.
Source: mp.weixin.qq.com · mp.weixin.qq.com